This was the stock's second consecutive day of losses.

Bio-Techne Corp. closed 7.97% below its 52-week high of $85.57, which the company reached on May 15th.

In a report released on January 10, Conor McNamara from RBC Capital maintained a Hold rating on Bio-Techne (TECH – Research Report), with a ...

These products are not directly competing with other spatial platform technologies. Bio-Techne is well-known for its RNAscope ...

MINNEAPOLIS, Jan. 10, 2025 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global leader in life science tools and reagents, today announced the launch of new designer proteins engineered using ...

(RTTNews) - Bio-Techne Corp. (TECH), a life sciences company, announced Tuesday that it has won a second claim of reverse engineering by Miltenyi Biotec B.V. & Co. KG, which may appeal the Court's ...

Bio-Techne (TECH) prevailed on another claim that Miltenyi Biotec KG commercialized antibodies developed based on information obtained by ...

Bio-Techne (TECH) prevailed on another claim that Miltenyi Biotec KG commercialized antibodies developed based on information obtained by reverse engineering Bio-Techne’s proprietary R&D Systems ...

MINNEAPOLIS, Jan. 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on another claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies ...

Minnesota-based medical equipment manufacturer Bio-Techne plans to double the size of its laboratory and manufacturing center at 5 Technology Drive with a 54,000-square-foot addition. The Planning ...